Infliximab exerts no direct hepatotoxic effect on HepG2 cells in vitro

Digestive Diseases and Sciences

Volumn 57, Issue 6, 2012, Pages 1604-1608

  De Vries, Hilbert S ^a   De Heij, Tineke ^a   Roelofs, Henie M J ^a   Te Morsche, Rene H M ^a   Peters, Wilbert H M ^a   De Jong, Dirk J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

6 mercaptopurine; 6 thioguanine; Azathioprine; Hepatotoxicity; HepG2 cells; Inflammatory bowel disease; Infliximab; Methotrexate

Indexed keywords

AZATHIOPRINE; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; TIOGUANINE;

ARTICLE; CELL STRAIN HEPG2; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EXPOSURE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LIVER TOXICITY; PRIORITY JOURNAL;

6-MERCAPTOPURINE; ANALYSIS OF VARIANCE; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HEP G2 CELLS; HEPATOBLASTOMA; HUMANS; INFLAMMATORY BOWEL DISEASES; LIVER NEOPLASMS; METHOTREXATE; SENSITIVITY AND SPECIFICITY; THIOGUANINE;

EID: 84864285492     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-012-2159-7     Document Type: Article

References (27)

1. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med. 2006;354:731-739. (Pubitemid 43247143)
2. Rogler G. Gastrointestinal and liver adverse effects of drugs used for treating IBD. Best Pract Res Clin Gastroenterol. 2010;24: 157-165.
3. Khokhar OS, Lewis JH. Hepatotoxicity of agents used in the management of inflammatory bowel disease. Dig Dis. 2010;28: 508-518.
4. US Food and Drug Association (2004) MedWatch safety alerts for human medical products. http://www.fda.gov/medWatch/safety/2004/remicade-DHCP-dec04. pdf. Accessed 5 April 2012
5. Federal Drug Administration (2009) REMICADE® (infliximab)for IV Injection. http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/ 103772s5234lbl.pdf. Accessed 5 April 2012
6. Sokolove J, Strand V, Greenberg JD, et al. Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. Ann Rheum Dis. 2010;69:1612-1617.
7. Mancini S, Amorotti E, Vecchio S, et al. Infliximab-related hepatitis: discussion of a case and review of the literature. Intern Emerg Med. 2010;5:193-200.
8. Ierardi E, Valle ND, Nacchiero MC, et al. Onset of liver damage after a single administration of infliximab in a patient with refractory ulcerative colitis. Clin Drug Investig. 2006;26:673-676. (Pubitemid 44627852)
9. Yeon JH, Na D, Park JK. Hepatotoxicity assay using human hepatocytes trapped in microholes of a microfluidic device. Electrophoresis. 2010;31:3167-3174.
10. Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117:244-279.
11. Johansson AG, Sundqvist T, Skogh T. IgG immune complex binding to and activation of liver cells. An in vitro study with IgG immune complexes, Kupffer cells, sinusoidal endothelial cells and hepatocytes. Int Arch Allergy Immunol. 2000;121:329-336. (Pubitemid 30229646)
12. Aithal GP. Hepatotoxicity related to antirheumatic drugs. Nat Rev Rheumatol. 2011;7:139-150.
13. Rojas JR, Taylor RP, Cunningham MR, et al. Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys. J Pharmacol Exp Ther. 2005;313:578-585. (Pubitemid 40604157)
14. Ferraro-Peyret C, Coury F, Tebib JG, et al. Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study. Arthritis Res Ther. 2004;6:R535-R543.
15. D'Auria F, Rovere-Querini P, Giazzon M, et al. Accumulation of plasma nucleosomes upon treatment with anti-tumour necrosis factor-alpha antibodies. J Intern Med. 2004;255:409-418. (Pubitemid 38315283)
16. Akerman P, Cote P, Yang SO, et al. Antibodies to tumor necrosis factor-alpha inhibit liver regeneration after partial hepatectomy. Am J Physiol. 1992;263:G579-G585.
17. Bruccoleri A, Gallucci R, Germolec DR, et al. Induction of early-immediate genes by tumor necrosis factor alpha contribute to liver repair following chemical-induced hepatotoxicity. Hepatology. 1997;25:133-141. (Pubitemid 27014999)
18. Brenndörfer ED, Weiland M, Frelin L, et al. Anti-tumor necrosis factor a treatment promotes apoptosis and prevents liver regeneration in a transgenic mouse model of chronic hepatitis C. Hepatology. 2010;52:1553-1563.
19. Petit E, Langouet S, Akhdar H, et al. Differential toxic effects of azathioprine, 6-mercaptopurine and 6-thioguanine on human hepatocytes. Toxicol In Vitro. 2008;22:632-642.
20. Yin J, Meng Q, Zhang G, et al. Differential methotrexate hepatotoxicity on rat hepatocytes in 2-D monolayer culture and 3-D gel entrapment culture. Chem Biol Interact. 2009;180:368-375.
21. Egan LJ, Sandborn WJ, Mays DC, et al. Systemic and intestinal pharmacokinetics of methotrexate in patients with inflammatory bowel disease. Clin Pharmacol Ther. 1999;65:29-39. (Pubitemid 29062026)
22. Tostmann A, Boeree MJ, Peters WHM, et al. Isoniazid and its toxic metabolite hydrazine induce in vitro pyrazinamide toxicity. Int J Antimicrob Agents. 2008;31:577-580.
23. Zimm S, Collins JM, Riccardi R, et al. Variable bioavailability of oral mercaptopurine: is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered? N Engl J Med. 1983;308:1005-1009. (Pubitemid 13118706)
24. Ding TL, Benet LZ. Comparative bioavailability and pharmaco-kinetic study of azathioprine and 6-mercaptopurine in the rhesus monkey. Drug Metab Dispos. 1979;7:373-377. (Pubitemid 10176111)
25. Deibert P, Dilger K, Fischer C, et al. High variation of tioguanine absorption in patients with chronic active Crohn's disease. Aliment Pharmacol Ther. 2003;18:183-189. (Pubitemid 36951654)
26. Chan GL, Canafax DM, Johnson CA. The therapeutic use of azathioprine in renal transplantation. Pharmacotherapy. 1987;7: 165-177. (Pubitemid 18001594)
27. Wilkening S, Bader A. Influence of culture time on the expression of drug-metabolizing enzymes in primary human hepato-cytes and hepatoma cell line HepG2. J Biochem Mol Toxicol. 2003;17:207-213. (Pubitemid 36974720)